Healthcare provider profile · identity verified

Michael Lee Bartlett, MD

Family Practice · LONGVIEW, WA · NPI 1356348502

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	213	52
Atorvastatin Calcium	Atorvastatin Calcium	201	58
Lisinopril	Lisinopril	195	53
Amlodipine Besylate	Amlodipine Besylate	141	39
Lovastatin	Lovastatin	140	34
Omeprazole	Omeprazole	120	31
Tamsulosin Hcl	Tamsulosin Hcl	110	27
Montelukast Sodium	Montelukast Sodium	108	22
Gabapentin	Gabapentin	103	25
Metformin Hcl	Metformin Hcl	102	26
Metoprolol Succinate	Metoprolol Succinate	94	26
Losartan Potassium	Losartan Potassium	93	29
Oxycodone Hcl	Oxycodone Hcl	82	17
Ozempic	Semaglutide	79	13
Albuterol Sulfate Hfa	Albuterol Sulfate	78	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	15
Buspirone Hcl	Buspirone Hcl	57	12
Potassium Chloride	Potassium Chloride	56	19
Simvastatin	Simvastatin	55	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	28
Hydrochlorothiazide	Hydrochlorothiazide	52	17
Sertraline Hcl	Sertraline Hcl	52	14
Hydroxyzine Hcl	Hydroxyzine Hcl	50	16
Metformin Hcl Er	Metformin Hcl	49	15
Trazodone Hcl	Trazodone Hcl	49	12
Carvedilol	Carvedilol	48	14
Finasteride	Finasteride	47	14
Metoprolol Tartrate	Metoprolol Tartrate	42	15
Bupropion Hcl Sr	Bupropion Hcl	41	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Fluticasone Propionate	Fluticasone Propionate	38	14
Furosemide	Furosemide	38	13
Tramadol Hcl	Tramadol Hcl	36	15
Ondansetron Odt	Ondansetron	35	suppressed
Allopurinol	Allopurinol	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Eliquis	Apixaban	34	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	suppressed
Celecoxib	Celecoxib	33	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	11
Glipizide Er	Glipizide	31	suppressed
Atenolol	Atenolol	30	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Clonazepam	Clonazepam	28	suppressed
Famotidine	Famotidine	26	suppressed
Jardiance	Empagliflozin	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Lamotrigine	Lamotrigine	24	suppressed
Lorazepam	Lorazepam	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Doxycycline Ir-Dr	Doxycycline Monohydrate	14	suppressed
Prednisone	Prednisone	14	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Topiramate	Topiramate	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Modafinil	Modafinil	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error